Re: Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

[Timothy Cook]

Why?

https://rxnav.nlm.nih.gov/InteractionAPIs.html#



On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce  wrote:

> (FYI for folks on the public-semweb-lifesci list who are not participating
> in the task force [1])
>
> Hello,
>
> Below I have pasted the minutes from the last meeting of the content
> sub-team for the DDI Minimum Information Model task force [1].  I apologize
> that I was forgot to record the meeting but I have tried to write detailed
> minutes. The full set of minutes for the task force are available [2].
>
> 1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
> 2. https://goo.gl/TKWfNN
>
> 
> Minutes for 2/24/2016 (Content subgroup)
>
> In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh,
> Richard Boyce, Sam Habiel
>
> Meeting recording: None taken (Rich forgot to start the recording, Sorry!)
>
> Meeting:
>
>-
>
>Brief discussion of progress on the proposed task force activities:
>
>
>
>1.
>
>Clarify definitions for the seven minimum information items
>recommended by prior AHRQ drug interaction conference series
>-
>
>   A sub-team has been working on creating definitions. Initial ideas
>   have been developed and will be discussed over the next month:
>   https://goo.gl/N0MxPd
>   -
>
>   Some questions were raised by the sub-team that were discussed
>   later during the meeting.
>
>
>
>1.
>
>Propose additional attributes
>-
>
>   Depends on Activity 1
>
>
>
>1.
>
>Create deliverables using an interesting and non-trivial set of
>potential drug-drug interactions:
>-
>
>   Depends on Activities 1 and 2
>   2.
>
>Create a foundation for further collaborative work by disseminating
>results through an interest group note, a website, and an online discussion
>forum
>-
>
>   Ratnesh Sahay has created a project that will be used for advancing
>   development of the interest group note:
>   
>   https://github.com/W3C-HCLS/w3c-ddi
>   1.
>
>  A very initial outline can be seen here: 
>  http://goo.gl/ZMU1Wm
>  2.
>
>  All persons who have participated in the calls have been listed
>  as contributors for now (in alphabetical order by first name). 
> Please email
>  Rich Boyce with spelling corrections and the affiliation you would 
> like (or
>  if you would like your name removed)
>  -
>
>   Scott Nelson submitted a panel proposal on 3/10 to AMIA to discuss
>   the topic of including seriousness as a minimum information item
>
>
>
>-
>
>Discussion of what DDI content to include in our deliverables.
>-
>
>   Sub-team members had made progress on suggesting interacting pairs
>   based on known issues with DDI evidence and knowledge
>   -
>
>  See https://goo.gl/rYpmjt
>  -
>
>   Rich created a survey to increase the participation:
>   
>   https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X
>   -
>
>  Survey closes EOB Wednesday 3/30
>  -
>
>   It was decided that only one or two PDDIs will be selected for each
>   category. The group agreed that, for each PDDI, a decision tree will be
>   created that provides 1) information that can help contextualize the
>   interaction depending on drug and patient factors, 2) management
>   recommendations depending on the contextualizing factors in (1), and 3)
>   evidence supporting or refuting each scientific claim made for (1)
>   -
>
>  Such decision trees have already been created by John Horn and
>  Phil Hansten for several interactions as part of Dan Malone’s AHRQ 
> grant
>  (R21HS023826).
>  -
>
> These can be used for the project as long as we provide
> citation to the authors and grant.
> -
>
> These interactions might fit as representative for certain
> information categories. The group agreed that, for those cases, 
> additional
> interactions will be chosen to provide heterogeneity
> -
>
>Discussion of stakeholders
>-
>
>   The question of who the stakeholders are for the min info model
>   came up from the Standard sub-team. The content sub-team agreed that the
>   stakeholders included primarily the following:
>   -
>
>  Clinicians (doctors, nurses, pharmacists, and various
>  practitioners) who must use PDDI information to make clinical 
> decisions
>  -
>
>  Persons who create systems that provide PDDI information to
>  clinicians in various settings (e.g., database vendors, drug 
> information
>  editorial boards)
>  -
>
>  Organizations that provide publicly available lists 

Re: Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

[Timothy Cook]

On Sun, Mar 27, 2016 at 6:32 AM, Timothy Cook  wrote:

>
>
> Apologies for being to vague.  Why are people doing this DDI work when
> this great resource is already available?
> If ou are not familiar with RxNorm, a little bit of observation and
> reading will explain what it is.
>
>
Opps, 'too vague'  and 'If you'.  Early morning fingers I guess.  :-)




>
>
>>
>>
>> *From:* Timothy Cook [mailto:t...@datainsights.tech]
>> *Sent:* Saturday, March 26, 2016 3:30 PM
>> *To:* Richard Boyce
>> *Cc:* public-semweb-lifesci@w3.org; linik...@gmail.com;
>> brian.leba...@va.gov; bho...@genelex.com; cjvit...@partners.org;
>> cui@uth.tmc.edu; mal...@pharmacy.arizona.edu;
>> daniela.olive...@insight-centre.org; e...@squishymedia.com;
>> draper.e...@mayo.edu; george.li...@va.gov; gmce...@ashp.org;
>> jschnei...@pobox.com; har...@pitt.edu; jeffniel...@gmail.com;
>> sundaram.medimm...@gmail.com; jrh...@u.washington.edu; jkli...@ncpdp.org;
>> j...@rxdoc.me; jmba...@stanford.edu; ka...@pitt.edu; kim.no...@pfizer.com;
>> laura.slaugh...@gmail.com; lori.idem...@gmail.com;
>> pet...@pharmacy.arizona.edu; maria.herr...@kcl.ac.uk;
>> breitenstein.matt...@mayo.edu; mbrochhau...@uams.edu;
>> matthias.samw...@meduniwien.ac.at; michel.dumont...@stanford.edu;
>> michael.mil...@systemsbiology.org; michael.lieb...@ipqanalytics.com;
>> m...@jackpo.org; na...@worldvista.org; nick.tatone...@columbia.edu;
>> hassanza...@us.ibm.com; yongq...@med.umich.edu; oliv...@nlm.nih.gov;
>> be...@dbis.rwth-aachen.de; nyt...@idi.ntnu.no;
>> ratnesh.sa...@insight-centre.org; freimuth.rob...@mayo.edu;
>> sam.hab...@gmail.com; scott.nelson...@gmail.com; serkanay...@gmail.com;
>> vale...@genelex.com; xjing2...@gmail.com
>> *Subject:* Re: Minutes from the 2/24/16 DDI Information task force
>> discussion (content sub group)
>>
>>
>>
>> Why?
>>
>>
>>
>> https://rxnav.nlm.nih.gov/InteractionAPIs.html#
>> <https://rxnav.nlm.nih.gov/InteractionAPIs.html>
>>
>>
>>
>>
>>
>>
>>
>> On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce  wrote:
>>
>> (FYI for folks on the public-semweb-lifesci list who are not
>> participating in the task force [1])
>>
>> Hello,
>>
>> Below I have pasted the minutes from the last meeting of the content
>> sub-team for the DDI Minimum Information Model task force [1].  I apologize
>> that I was forgot to record the meeting but I have tried to write detailed
>> minutes. The full set of minutes for the task force are available [2].
>>
>> 1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
>> 2. https://goo.gl/TKWfNN
>>
>> 
>> Minutes for 2/24/2016 (Content subgroup)
>>
>>
>>
>> *In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh,
>> Richard Boyce, Sam Habiel*
>>
>>
>>
>> Meeting recording: None taken (Rich forgot to start the recording,
>> Sorry!)
>>
>>
>>
>> Meeting:
>>
>> · Brief discussion of progress on the *proposed task force
>> activities:*
>>
>>
>>
>> 1.*Clarify definitions *for the seven minimum information items
>> recommended by prior AHRQ drug interaction conference series
>>
>> oA sub-team has been working on creating definitions. Initial ideas
>> have been developed and will be discussed over the next month:
>> https://goo.gl/N0MxPd
>>
>> oSome questions were raised by the sub-team that were discussed
>> later during the meeting.
>>
>>
>>
>> 2.*Propose additional attributes*
>>
>> oDepends on Activity 1
>>
>>
>>
>> 3.*Create deliverables* using an interesting and non-trivial set of
>> potential drug-drug interactions:
>>
>> oDepends on Activities 1 and 2
>>
>> 4.*Create a foundation for further collaborative work* by
>> disseminating results through an interest group note, a website, and an
>> online discussion forum
>>
>> oRatnesh Sahay has created a project that will be used for advancing
>> development of the interest group note:
>> https://github.com/W3C-HCLS/w3c-ddi
>>
>>   i.A very initial outline
>> can be seen here: http://goo.gl/ZMU1Wm
>>
>>  ii.All persons who have
>> participated in the calls have been listed as contributors for now (in
>> alphabetical order by first name). Please email Rich Bo

Re: Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

[Timothy Cook]

On Sat, Mar 26, 2016 at 11:45 PM, jrhorn  wrote:

> Tim
>
>
>
> Not sure why. Not sure what it does. This is difficult to load, but it
> looks like it is a DrugBank database. I would avoid using for any clinical
> purpose.
>
>
>
> What is it?
>
>
>
> John
>


Apologies for being to vague.  Why are people doing this DDI work when this
great resource is already available?
If ou are not familiar with RxNorm, a little bit of observation and reading
will explain what it is.



>
>
> *From:* Timothy Cook [mailto:t...@datainsights.tech]
> *Sent:* Saturday, March 26, 2016 3:30 PM
> *To:* Richard Boyce
> *Cc:* public-semweb-lifesci@w3.org; linik...@gmail.com;
> brian.leba...@va.gov; bho...@genelex.com; cjvit...@partners.org;
> cui@uth.tmc.edu; mal...@pharmacy.arizona.edu;
> daniela.olive...@insight-centre.org; e...@squishymedia.com;
> draper.e...@mayo.edu; george.li...@va.gov; gmce...@ashp.org;
> jschnei...@pobox.com; har...@pitt.edu; jeffniel...@gmail.com;
> sundaram.medimm...@gmail.com; jrh...@u.washington.edu; jkli...@ncpdp.org;
> j...@rxdoc.me; jmba...@stanford.edu; ka...@pitt.edu; kim.no...@pfizer.com;
> laura.slaugh...@gmail.com; lori.idem...@gmail.com;
> pet...@pharmacy.arizona.edu; maria.herr...@kcl.ac.uk;
> breitenstein.matt...@mayo.edu; mbrochhau...@uams.edu;
> matthias.samw...@meduniwien.ac.at; michel.dumont...@stanford.edu;
> michael.mil...@systemsbiology.org; michael.lieb...@ipqanalytics.com;
> m...@jackpo.org; na...@worldvista.org; nick.tatone...@columbia.edu;
> hassanza...@us.ibm.com; yongq...@med.umich.edu; oliv...@nlm.nih.gov;
> be...@dbis.rwth-aachen.de; nyt...@idi.ntnu.no;
> ratnesh.sa...@insight-centre.org; freimuth.rob...@mayo.edu;
> sam.hab...@gmail.com; scott.nelson...@gmail.com; serkanay...@gmail.com;
> vale...@genelex.com; xjing2...@gmail.com
> *Subject:* Re: Minutes from the 2/24/16 DDI Information task force
> discussion (content sub group)
>
>
>
> Why?
>
>
>
> https://rxnav.nlm.nih.gov/InteractionAPIs.html#
> <https://rxnav.nlm.nih.gov/InteractionAPIs.html>
>
>
>
>
>
>
>
> On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce  wrote:
>
> (FYI for folks on the public-semweb-lifesci list who are not participating
> in the task force [1])
>
> Hello,
>
> Below I have pasted the minutes from the last meeting of the content
> sub-team for the DDI Minimum Information Model task force [1].  I apologize
> that I was forgot to record the meeting but I have tried to write detailed
> minutes. The full set of minutes for the task force are available [2].
>
> 1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
> 2. https://goo.gl/TKWfNN
>
> 
> Minutes for 2/24/2016 (Content subgroup)
>
>
>
> *In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh,
> Richard Boyce, Sam Habiel*
>
>
>
> Meeting recording: None taken (Rich forgot to start the recording, Sorry!)
>
>
>
> Meeting:
>
> · Brief discussion of progress on the *proposed task force
> activities:*
>
>
>
> 1.*Clarify definitions *for the seven minimum information items
> recommended by prior AHRQ drug interaction conference series
>
> oA sub-team has been working on creating definitions. Initial ideas
> have been developed and will be discussed over the next month:
> https://goo.gl/N0MxPd
>
> oSome questions were raised by the sub-team that were discussed later
> during the meeting.
>
>
>
> 2.*Propose additional attributes*
>
> oDepends on Activity 1
>
>
>
> 3.*Create deliverables* using an interesting and non-trivial set of
> potential drug-drug interactions:
>
> oDepends on Activities 1 and 2
>
> 4.*Create a foundation for further collaborative work* by
> disseminating results through an interest group note, a website, and an
> online discussion forum
>
> oRatnesh Sahay has created a project that will be used for advancing
> development of the interest group note:
> https://github.com/W3C-HCLS/w3c-ddi
>
>   i.A very initial outline
> can be seen here: http://goo.gl/ZMU1Wm
>
>  ii.All persons who have
> participated in the calls have been listed as contributors for now (in
> alphabetical order by first name). Please email Rich Boyce with spelling
> corrections and the affiliation you would like (or if you would like your
> name removed)
>
> oScott Nelson submitted a panel proposal on 3/10 to AMIA to discuss
> the topic of including seriousness as a minimum information item
>
>
>
> · Discussion of what DDI content to include in our deliverabl

Re: Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

[Jodi Schneider]

Thanks, Tim. We're coming from a variety of backgrounds -- with a range of
informatics expertise and clinical pharmacy expertise. On the informatics
side, RxNorm is definitely in active use.

However, there's a large gap between resources appropriate for systems
development and those used for clinical purposes [1]. There's a lot of work
needed to close this gap. The minimal information model we are developing
is a start, in making a knowledge representation that can (compactly,
computably) record the clinically relevant information.

More informatics expertise is always welcome -- the standards part of the
taskforce meets Thursday if you want to get involved:
https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce

-Jodi

[1] You'll see, for instance, that for side effects and interactions the
NLM itself doesn't recommend the RxNorm's Drug Interactions API but rather
clinical information, including John Horn's “Drug Interactions Analysis and
Management”:
https://www.nlm.nih.gov/services/Subject_Guides/druginformation/specializedaspects/sideeffectsandinteractions/index.html



On Sun, Mar 27, 2016 at 5:33 AM, Timothy Cook  wrote:

>
>
> On Sun, Mar 27, 2016 at 6:32 AM, Timothy Cook 
> wrote:
>
>>
>>
>> Apologies for being to vague.  Why are people doing this DDI work when
>> this great resource is already available?
>> If ou are not familiar with RxNorm, a little bit of observation and
>> reading will explain what it is.
>>
>>
> Opps, 'too vague'  and 'If you'.  Early morning fingers I guess.  :-)
>
>
>
>
>>
>>
>>>
>>>
>>> *From:* Timothy Cook [mailto:t...@datainsights.tech]
>>> *Sent:* Saturday, March 26, 2016 3:30 PM
>>> *To:* Richard Boyce
>>> *Cc:* public-semweb-lifesci@w3.org; linik...@gmail.com;
>>> brian.leba...@va.gov; bho...@genelex.com; cjvit...@partners.org;
>>> cui@uth.tmc.edu; mal...@pharmacy.arizona.edu;
>>> daniela.olive...@insight-centre.org; e...@squishymedia.com;
>>> draper.e...@mayo.edu; george.li...@va.gov; gmce...@ashp.org;
>>> jschnei...@pobox.com; har...@pitt.edu; jeffniel...@gmail.com;
>>> sundaram.medimm...@gmail.com; jrh...@u.washington.edu; jkli...@ncpdp.org;
>>> j...@rxdoc.me; jmba...@stanford.edu; ka...@pitt.edu; kim.no...@pfizer.com;
>>> laura.slaugh...@gmail.com; lori.idem...@gmail.com;
>>> pet...@pharmacy.arizona.edu; maria.herr...@kcl.ac.uk;
>>> breitenstein.matt...@mayo.edu; mbrochhau...@uams.edu;
>>> matthias.samw...@meduniwien.ac.at; michel.dumont...@stanford.edu;
>>> michael.mil...@systemsbiology.org; michael.lieb...@ipqanalytics.com;
>>> m...@jackpo.org; na...@worldvista.org; nick.tatone...@columbia.edu;
>>> hassanza...@us.ibm.com; yongq...@med.umich.edu; oliv...@nlm.nih.gov;
>>> be...@dbis.rwth-aachen.de; nyt...@idi.ntnu.no;
>>> ratnesh.sa...@insight-centre.org; freimuth.rob...@mayo.edu;
>>> sam.hab...@gmail.com; scott.nelson...@gmail.com; serkanay...@gmail.com;
>>> vale...@genelex.com; xjing2...@gmail.com
>>> *Subject:* Re: Minutes from the 2/24/16 DDI Information task force
>>> discussion (content sub group)
>>>
>>>
>>>
>>> Why?
>>>
>>>
>>>
>>> https://rxnav.nlm.nih.gov/InteractionAPIs.html#
>>> <https://rxnav.nlm.nih.gov/InteractionAPIs.html>
>>>
>>>
>>>
>>>
>>>
>>>
>>>
>>> On Sat, Mar 26, 2016 at 1:01 PM, Richard Boyce  wrote:
>>>
>>> (FYI for folks on the public-semweb-lifesci list who are not
>>> participating in the task force [1])
>>>
>>> Hello,
>>>
>>> Below I have pasted the minutes from the last meeting of the content
>>> sub-team for the DDI Minimum Information Model task force [1].  I apologize
>>> that I was forgot to record the meeting but I have tried to write detailed
>>> minutes. The full set of minutes for the task force are available [2].
>>>
>>> 1.
>>> https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
>>> 2. https://goo.gl/TKWfNN
>>>
>>> 
>>> Minutes for 2/24/2016 (Content subgroup)
>>>
>>>
>>>
>>> *In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh,
>>> Richard Boyce, Sam Habiel*
>>>
>>>
>>>
>>> Meeting recording: None taken (Rich forgot to start the recording,
>>> Sorry!)
>>>
>>>
>>>
>>> Meeting:
>>>
>>> · Brief discussion of progress on the *pro

Minutes from the 2/24/16 DDI Information task force discussion (content sub group)

[Richard Boyce]

(FYI for folks on the public-semweb-lifesci list who are not 
participating in the task force [1])


Hello,

Below I have pasted the minutes from the last meeting of the content 
sub-team for the DDI Minimum Information Model task force [1].  I 
apologize that I was forgot to record the meeting but I have tried to 
write detailed minutes. The full set of minutes for the task force are 
available [2].


1. https://sites.google.com/site/ddikrandir/home/ddi_info_model_taskforce
2. https://goo.gl/TKWfNN




   Minutes for 2/24/2016 (Content subgroup)


In Attendance : Dan Malone, Evan Draper, John Horn, Oktie Hassanzadeh, 
Richard Boyce, Sam Habiel



Meeting recording: None taken (Rich forgot to start the recording, Sorry!)


Meeting:

 *

   Brief discussion of progress on the proposed task force activities:


1.

   Clarify definitions for the seven minimum information items
   recommended by prior AHRQ drug interaction conference series

 *

   A sub-team has been working on creating definitions. Initial
   ideas have been developed and will be discussed over the next
   month: https://goo.gl/N0MxPd

 *

   Some questions were raised by the sub-team that were discussed
   later during the meeting.


2.

   Propose additional attributes

 *

   Depends on Activity 1


3.

   Create deliverablesusing an interesting and non-trivial set of
   potential drug-drug interactions:

 *

   Depends on Activities 1 and 2

4.

   Create a foundation for further collaborative workby disseminating
   results through an interest group note, a website, and an online
   discussion forum

 *

   Ratnesh Sahay has created a project that will be used for
   advancing development of the interest group note:
   https://github.com/W3C-HCLS/w3c-ddi

1.

   A very initial outline can be seen here: http://goo.gl/ZMU1Wm

2.

   All persons who have participated in the calls have been
   listed as contributors for now (in alphabetical order by
   first name). Please email Rich Boyce with spelling
   corrections and the affiliation you would like (or if you
   would like your name removed)

 *

   Scott Nelson submitted a panel proposal on 3/10 to AMIA to
   discuss the topic of including seriousness as a minimum
   information item


 *

   Discussion of what DDI content to include in our deliverables.

 o

   Sub-team members had made progress on suggesting interacting
   pairs based on known issues with DDI evidence and knowledge

 +

   See https://goo.gl/rYpmjt

 o

   Rich created a survey to increase the participation:
   https://pitt.co1.qualtrics.com/jfe/form/SV_0GPfzm7UbGDYV5X

 +

   Survey closes EOB Wednesday 3/30

 o

   It was decided that only one or two PDDIs will be selected for
   each category. The group agreed that, for each PDDI, a decision
   tree will be created that provides 1) information that can help
   contextualize the interaction depending on drug and patient
   factors, 2) management recommendations depending on the
   contextualizing factors in (1), and 3) evidence supporting or
   refuting each scientific claim made for (1)

 +

   Such decision trees have already been created by John Horn
   and Phil Hansten for several interactions as part of Dan
   Malone’s AHRQ grant (R21HS023826).

 #

   These can be used for the project as long as we provide
   citation to the authors and grant.

 #

   These interactions might fit as representative for
   certain information categories. The group agreed that,
   for those cases, additional interactions will be chosen
   to provide heterogeneity

 *

   Discussion of stakeholders

 o

   The question of who the stakeholders are for the min info model
   came up from the Standard sub-team. The content sub-team agreed
   that the stakeholders included primarily the following:

 +

   Clinicians (doctors, nurses, pharmacists, and various
   practitioners) who must use PDDI information to make
   clinical decisions

 +

   Persons who create systems that provide PDDI information to
   clinicians in various settings (e.g., database vendors, drug
   information editorial boards)

 +

   Organizations that provide publicly available lists of
   drug-drug interactions (e.g., developers of RxNorm)

 o

   Clarification of this in writing is planned

 *

   Discussion of use cases:

 o

   Members of the standard sub-team had suggested using Medication
   Reconciliation as a target use case for showing the value of the
   info model (e.g., competency questions). Rich asked the content